Myeloperoxidase and oxidation of uric acid in gout: Implications for the clinical consequences of hyperuricaemia

Rheumatology (United Kingdom)

Volumn 53, Issue 11, 2014, Pages 1958-1965

  Stamp, Lisa K ^a   Turner, Rufus ^a   Khalilova, Irada S ^a   Zhang, Mei ^b   Drake, Jill ^b   Forbes, Louisa V ^a   Kettle, Anthony J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

Allopurinol; Cardiovascular disease; Gout; Myeloperoxidase; Oxidative stress; Urate

Indexed keywords

ALLANTOIN; ALLOPURINOL; MYELOPEROXIDASE; OXIPURINOL; URATE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; GOUT; HUMAN; HYPERURICEMIA; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; OXIDATION; TREATMENT DURATION; URIC ACID BLOOD LEVEL;

EID: 84911499224     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu218     Document Type: Article

References (49)

1. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811-21.
2. McQueen FM, Chhana A, Dalbeth N. Mechanisms of joint damage in gout: evidence from cellular and imaging studies. Nat Rev Rheumatol 2012;8:173-81.
3. Krishnan E. Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Rheumatology 2010; 49:1229-38.
4. Rosendorff C, Jogendra MR. Uric acid: where are we? J Clin Hypertens 2013;15:5-6.
5. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41.
6. Bagnati M, Perugini C, Cau C et al. When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid. Biochem J 1999;340:143-52.
7. Meotti FC, Jameson GN, Turner R et al. Urate as a physiological substrate for myeloperoxidase: implications for hyperuricemia and inflammation. J Biol Chem 2011; 286:12901-11.
8. Kettle AJ, Winterbourn CC. Myeloperoxidase: a key regulator of neutrophil oxidant production. Redox Rep 1997;3:3-15.
9. Frei B, Stocker R, Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci USA 1988;85:9748-52.
10. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005;25: 1102-11.
11. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006;54:2688-96.
12. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008;168: 1104-10.
13. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116:894-900.
14. Edwards NL. The role of hyperuricemia in vascular disorders. Curr Opin Rheumatol 2009;2:132-7.
15. Zhang W, Doherty M, Bardin T et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
16. Cantu-Medellin N, Kelley EE. Xanthine oxidoreductasecatalyzed reactive species generation: a process in critical need of reevaluation. Redox Biol 2013;1:353-8.
17. Day RO, Graham GG, Hicks M et al. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet 2007;46:623-44.
18. Wallace SL, Robinson H, Masi AT et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
19. Stamp LK, Khalilova I, Tarr JM et al. Myeloperoxidase and oxidative stress in rheumatoid arthritis. Rheumatology 2012;51:1796-803.
20. Jen JF, Hsiao SL, Liu KH. Simultaneous determination of uric acid and creatinine in urine by an eco-friendly solventfree high performance liquid chromatographic method. Talanta 2002;58:711-7.
21. Stamp LK, Barclay ML, O'Donnell JL et al. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clin Pharmacol Ther 2011;90:392-8.
22. Graham S, Day RO, Wong H et al. Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects. Br J Clin Pharmacol 1996;41:299-304.
23. Chapman AL, Mocatta TJ, Shiva S et al. Ceruloplasmin is an endogenous inhibitor of myeloperoxidase. J Biol Chem 2013;288:6465-77.
24. Turner R, Stamp LK, Kettle AJ. Detection of allantoin in clinical samples using hydrophilic liquid chromatography with stable isotope dilution negative ion tandem mass spectrometry. J Chromatogr B 2012;891-892:85-9.
25. Dypbukt JM, Bishop C, Brooks WM et al. A sensitive and selective assay for chloramine production by myeloperoxidase. Free Radic Biol Med 2005;39:1468-77.
26. Burt HM, Jackson JK. The priming action of tumour necrosis factor-alpha (TNF-alpha) and granulocytemacrophage colony-stimulating factor (GM-CSF) on neutrophils activated by inflammatory microcrystals. Clin Exp Immunol 1997;108:432-7.
27. Martinon F. Mechanisms of uric acid crystal-mediated autoinflammation. Immunol Rev 2010;233:218-32.
28. Thomas MJ. Urate causes the human polymorphonuclear leukocyte to secrete superoxide. Free Radic Biol Med 1992;12:89-91.
29. Paumann-Page M, Furtmuller PG, Hofbauer S et al. Inactivation of human myeloperoxidase by hydrogen peroxide. Arch Biochem Biophys 2013;539:51-62.
30. Maitra D, Shaeib F, Abdulhamid I et al. Myeloperoxidase acts as a source of free iron during steady-state catalysis by a feedback inhibitory pathway. Free Radic Biol Med 2013;63:90-8.
31. Marshall CJ, Nallaratnam M, Mocatta T et al. Factors influencing local and systemic levels of plasma myeloperoxidase in ST segment elevation acute myocardial infarction. Am J Cardiol 2010;106:316-22.
32. Kettle AJ, Chan T, Osberg I et al. Myeloperoxidase and protein oxidation in the airways of young children with cystic fibrosis. Am J Respir Crit Care Med 2004;170: 1317-23.
33. Hazell LJ, Arnold L, Flowers D et al. Presence of hypochlorite- modified proteins in human atherosclerotic lesions. J Clin Invest 1996;97:1535-44.
34. Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 1997;99: 2075-81.
35. Stevenson WS, Hyland CD, Zhang JG et al. Deficiency of 5-hydroxyisourate hydrolase causes hepatomegaly and hepatocellular carcinoma in mice. Proc Natl Acad Sci USA 2010;107:16625-30.
36. Alvarez-Lario B, Macarron-Vicente J. Uric acid and evolution. Rheumatology 2010;49:2010-5.
37. Tipton PA. Urate to allantoin, specifically (S)-allantoin. Nat Chem Biol 2006;2:124-5.
38. Kundu TK, Hille R, Velayutham M, Zweier JL. Characterization of superoxide production from aldehyde oxidase: an important source of oxidants in biological tissues. Arch Biochem Biophys 2007;460:113-21.
39. Kundu TK, Velayutham M, Zweier JL. Aldehyde oxidase functions as a superoxide generating NADH oxidase: an important redox regulated pathway of cellular oxygen radical formation. Biochemistry 2012;51:2930-9.
40. Kuo CF, See LC, Luo SF et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology 2010;49:141-6.
41. Nicholls SJ, Hazen SL. Myeloperoxidase, modified lipoproteins, and atherogenesis. J Lipid Res 2009;50(Suppl): S346-51.
42. Nussbaum C, Klinke A, Adam M, Baldus S, Sperandio M. Myeloperoxidase: a leukocyte-derived protagonist of inflammation and cardiovascular disease. Antioxid Redox Signal 2013;18:692-713.
43. Zheng L, Nukuna B, Brennan ML et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004;114:529-41.
44. Eiserich JP, Baldus S, Brennan ML et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002; 296:2391-4.
45. Vivekanandan-Giri A, Slocum JL, Byun J et al. High density lipoprotein is targeted for oxidation by myeloperoxidase in rheumatoid arthritis. Ann Rheum Dis 2013;72: 1725-31.
46. Stamp LK, Zhu X, Dalbeth N et al. Serum urate as a soluble biomarker in chronic gout-evidence that serum urate fulfills the OMERACT validation criteria for soluble biomarkers. Semin Arthritis Rheum 2011;40:483-500.
47. Becker MA, Schumacher HR Jr, Wortmann RL et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61.
48. Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009;36:1273-82.
49. Perez-Ruiz F, Herrero-Beites AM, Carmona L. A two-stage approach to the treatment of hyperuricemia in gout: the ''dirty dish'' hypothesis. Arthritis Rheum 2011;63:4002-6.